crizotinib + furmonertinib

Crizotinib + furmonertinib is a combination of two small molecule tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer (NSCLC) with specific genetic alterations. Crizotinib is a multitargeted TKI that inhibits anaplastic lymphoma kinase (ALK), ROS1, and MET kinases, while furmonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target EGFR mutations, including uncommon mutations and those associated with resistance to earlier EGFR-TKIs. This combination has been investigated for overcoming acquired resistance in NSCLC patients harboring both EGFR mutations and MET amplification, particularly after progression on prior EGFR-TKI therapies. Clinical case reports and small studies suggest that this dual inhibition can induce partial remission or disease control in patients with these molecular profiles[5][6]. Furmonertinib has demonstrated efficacy against CNS metastases due to its high brain penetration[2].

Other names

crizotinib + furmonertinib